• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Martin James Joseph

    7/20/23 4:05:28 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COCP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Martin James Joseph

    (Last) (First) (Middle)
    4400 BISCAYNE BLVD
    SUITE # 670

    (Street)
    MIAMI FL 33157

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Cocrystal Pharma, Inc. [ COCP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Co-CEO and CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    07/18/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (Right to Buy)(1) $2.67 07/18/2023 A 30,000 (2) 07/18/2033 Common Stock 30,000 $0 30,000 D
    Explanation of Responses:
    1. The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code").
    2. The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 18, 2024 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to continued employment on each applicable vesting date.
    /s/ James Martin 07/20/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $COCP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COCP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COCP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cocrystal Pharma Inc. (Amendment)

      SC 13G/A - Cocrystal Pharma, Inc. (0001412486) (Subject)

      1/2/24 9:53:56 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Cocrystal Pharma Inc. (Amendment)

      SC 13D/A - Cocrystal Pharma, Inc. (0001412486) (Subject)

      4/14/23 4:01:17 PM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cocrystal Pharma Inc.

      SC 13G - Cocrystal Pharma, Inc. (0001412486) (Subject)

      4/12/23 4:09:56 PM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COCP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

      CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company's virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits strong antiviral activity against the highly pathogenic H5N1 avian influenza A strain (A/Texas/37/2024). On March 25, 2024, the highly pathogenic avian H5N1 influenza virus was confirmed in a dairy cow in T

      5/29/25 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

      BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces that management will participate in a fireside chat during the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference on Thursday, June 5, 2025 at 12:00 p.m. (noon) Eastern time (9:00 a.m. Pacific time). Investors and interested individuals can register for the conference here. Questions from the audience during the live fireside chat will be welcomed. Registered, qualified investors can request one-on-one meetings with Cocrystal management through the conference registration platform. A video webcast of the presentation will be available within ap

      5/28/25 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

      In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "Our oral pan-viral protease inhibitor CDI-988 is a potential breakthrough first-in-class treatment and prophylaxis for norovirus, a debilitating gastrointestinal infection that strikes millions globally each year," said Sam Lee, Ph.D., President and co-CEO of Cocrystal. "By precisely targ

      5/15/25 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COCP
    Financials

    Live finance-specific insights

    See more
    • Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

      In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "Our oral pan-viral protease inhibitor CDI-988 is a potential breakthrough first-in-class treatment and prophylaxis for norovirus, a debilitating gastrointestinal infection that strikes millions globally each year," said Sam Lee, Ph.D., President and co-CEO of Cocrystal. "By precisely targ

      5/15/25 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

      BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "Our novel, potent antiviral compounds for norovirus, influenza and coronavirus address critical gaps in global health where effective treatments or vaccines are currently lacking," said Sam Lee, Ph.D., President and co-CEO of Cocrystal. "We plan to initiate a norovirus human challenge study in the U.S. later this year to evaluate our pan-viral protease inhibitor CDI-988 for the potential treatment and pr

      3/31/25 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

      BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three and nine months ended September 30, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "The coming months are critically important to Cocrystal as we expect to report topline results from two ongoing clinical studies with our best-in-class antiviral candidates in major medical indications," said Sam Lee, Ph.D., President and co-CEO of Cocrystal. "In the Phase 2a influenza A challenge study with our oral PB2 inhibitor CC-42344, we expect to report topline results before year

      11/13/24 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COCP
    Leadership Updates

    Live Leadership Updates

    See more
    • Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors

      BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six. Mr. Hassan's distinguished 40-year career includes serving in senior executive and director positions at global pharmaceutical companies and leading investment firms. Earlier this month, Cocrystal announced Mr. Hassan's $2 million investment in the Company through an at-the-market private placement. "It's an honor to attract such a highly accomplished industry veteran to our Board," said Roger Kornberg, PhD, Cocrystal Chairman, Chief Scientist and Chairman of the Scient

      4/24/23 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox

      BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of Cocrystal extend their deepest condolences to the Wilcox family and express their gratitude for Gary's contributions to Cocrystal and to human health. The Cocrystal Board of Directors has designated Sam Lee, Ph.D., President, and James Martin, CFO, to share the CEO responsibilities while seeking a successor for the position. Roger Kornberg, Ph.D., Cocrystal co-founder, Chief Scientist, Director and

      5/28/21 8:00:00 AM ET
      $OPK
      $ASXC
      $GPX
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Other Consumer Services

    $COCP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kornberg Roger D. was granted 28,109 shares (SEC Form 4)

      4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

      10/11/24 4:06:02 PM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Frost Phillip Md Et Al was granted 27,100 shares (SEC Form 4)

      4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

      10/11/24 4:06:00 PM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and Co-CEO Lee Sam was granted 40,000 shares, increasing direct ownership by 110% to 76,355 units (SEC Form 4)

      4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

      10/11/24 4:05:57 PM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COCP
    SEC Filings

    See more
    • Cocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)

      5/29/25 8:30:21 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cocrystal Pharma Inc.

      10-Q - Cocrystal Pharma, Inc. (0001412486) (Filer)

      5/15/25 8:30:27 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cocrystal Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)

      5/15/25 8:30:33 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care